CD4-Pseudomonas Exotoxin: A Strategy for AIDS Therapy Based on Selective Killing of HIV-Infected Cells

  • Per Ashorn
  • Bernard Moss
  • Edward A. Berger
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


The receptor for human immunodeficiency virus (HIV) is CD4, a 55 kD glycoprotein expressed on the surface of certain human lymphoid and monocytic cell types1. The finding2–7 that recombinant soluble forms of CD4 retain the capacity for high affinity binding to gp120 (the external subunit of the HIV envelope glycoprotein) has suggested potential therapeutic uses of CD4 derivatives. For example, soluble truncated forms of CD4 (sCD4) are able to neutralize HIV infectivity in vitro 2–6,suggesting they may have specific anti-viral activity in HIV-infected individuals. Several “second-generation” applications of this neutralizing concept are under development, including attachment of the CD4 to immunoglobulin constant region sequences8–12, or presentation of the CD4 in association with erythrocytes13. These modifications provide the advantages of increased plasma half-life compared to sCD4, and possibly enhanced efficiency of neutralization due to multivalency.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Infected Cell Line Selective Killing Human Immunodeficiency Virus Spread 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. R. Klatzman, J. S. McDougal, and P. J. Maddon, Tmmunodef. Rev. 2: 43 (1990).Google Scholar
  2. 2.
    D. H. Smith, R. A. Byrn, S. A. Marsters, T. Gregory, J. E. Groopman, and D. J. Capon, Science 238: 1704 (1987).PubMedCrossRefGoogle Scholar
  3. 3.
    R. A. Fisher, J. M. Bertonis, W. Meier, V. A. Johnson, D. S. Costopoulos, T. Liu, R. Tizard, B. D. Walker, M. S. Hirsch, R. T. Schooley, and R. A. Flavell, Nature 331: 76 (1988).PubMedCrossRefGoogle Scholar
  4. 4.
    R. E. Hussey, N. E. Richardson, M. Lowalski, N. R. Brown, H.-C. Chang, R. F. Siliciano, T. Dorfman, B. Walker, J. Sodroski, and E. L. Reinherz, Nature 331: 78 (1988).PubMedCrossRefGoogle Scholar
  5. 5.
    K. C. Deen, J. S. McDougal, R. Inacker, G. FolenaWasserman, J. Arthos, J. Rosenberg, P. J. Maddon, R. Axel and R. W. Sweet, Nature 331: 82 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    A. Traunecker, W. Luke, and K. Karjalainen, Nature 331: 84 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    E. A. Berger, T. R. Fuerst and B. Moss, Froc. Natl. Acad. Sci., USA 85: 2357 (1988).CrossRefGoogle Scholar
  8. 8.
    D. J. Capon, S. M. Chamow, J. Mordenti, S. A. Marsters, T. Gregory, H. Mitsuya, R. A. Byrn, C. Lucas, F. M. Wurm, J. E. Groopman, and D. H. Smith, Nature 337: 525 (1989).PubMedCrossRefGoogle Scholar
  9. 9.
    A. Traunecker, J. Schneider, H. Kiefer, and K. Karjalainen, Nature 339: 68 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    T. Mizukami, C. D. Smith, E. A. Berger, and B. Moss, Int. Conf. AIDS 5: 556 (1989).Google Scholar
  11. 11.
    R. A. Byrn, J. Mordenti, C. Lucas, D. Smith, S. A. Marsters, J. S. Johnson, P. Cossum, S. M. Chamow, F. M. Wurm, T. Gregory, J. E. Groopman, and D. J. Capon, Nature 344: 667 (1990).PubMedCrossRefGoogle Scholar
  12. 12.
    G. Zettlmeissl, J. P. Gregersen, J. M. Duport, S. Mehdi, G. Reiner, and B. Seed, DNA Cell. Biol. 9: 347 (1990).PubMedCrossRefGoogle Scholar
  13. 13.
    Y. Mouneimne, P. F. Tosi, R. Barhoumi, and C. Nicolau, Biochim. Biophys. Arta 1027: 53 (1990).CrossRefGoogle Scholar
  14. 14.
    V. K. Chaudhary, T. Mizukami, T. R. Fuerst, D. J. FitzGerald, B. Moss, I. Pastan, and E. A. Berger, Nature 333: 369 (1988).CrossRefGoogle Scholar
  15. 15.
    M. A. Till, V. Ghetie, T. Gregory, E. J. Patzer, J. P. Porter, J. W. Uhr, D. J. Capon, and E. S. Vitetta, Science 242: 1166 (1988).PubMedCrossRefGoogle Scholar
  16. 16.
    A. Cudd, C. A. Noonan, P. F. Tosi, J. L. Melnick, and C. Nicolau, I. Acquir. Immune Defic. Syndr. 3: 109 (1990).Google Scholar
  17. 17.
    I. Pastan and D. FitzGerald, I. Biol. Chem. 264: 15157 (1989).Google Scholar
  18. 18.
    E. A. Berger, K. A. Clouse, V. K. Chaudhary, S. Chakrabarti, D. J. FitzGerald, I. Pastan, and B. Moss, Proc. Natl. Acad. Sci. USA 86: 9539 (1989).PubMedCrossRefGoogle Scholar
  19. 19.
    E. A. Berger, V. K. Chaudhary, K. A. Clouse, D. Jaraquemada, J. A. Nicholas, K. L. Rubino, D. J. FitzGerald, I. Pastan, and B. Moss, AIDS Res. Hm. Retroviruses 6: 795 (1990).CrossRefGoogle Scholar
  20. 20.
    P. Ashorn, B. Moss, J. N. Weinstein, V. K. Chaudhary, D. J. FitzGerald, I. Pastan, and E. A. Berger, Proc. Natl. Acad. Sci USA 87: 8889 (1990).PubMedCrossRefGoogle Scholar
  21. 21.
    P. Ashorn, G. Englund, M. A. Martin, B. Moss, and E. A. Berger, submitted.Google Scholar
  22. 22.
    Z. F. Rosenberg and A. S. Fauci, AIDS Res. Hum. Retroviruses 5: 1 (1989).PubMedCrossRefGoogle Scholar
  23. 23.
    V. A. Johnson and M. S. Hirsch, in: “Antiviral Chemotherapy: New Directions for Clinical Applications and Research”, J. Mills and L. Corey, eds., Elsevier, New York, Vol. 2:275 (1989).Google Scholar
  24. 24.
    R. Yarchoan, H. Mitsuya, C. E. Myers, and S. Broder, N. Engl. J. Med. 321: 726 (1989).PubMedCrossRefGoogle Scholar
  25. 25.
    E. S. Daar, X. L. Li, T. Moudgil, and D. D. Ho, Proc. Natl. Acad. Sci., USA 87: 6574 (1990).PubMedCrossRefGoogle Scholar
  26. 26.
    L. N. Callahan and M. A. Norcross, Lancet 734 (1989).Google Scholar
  27. 27.
    H. Loberboum-Galski, L. V. Barrett, R. L. Kirkman, M. Ogata, M. C. Willingham, D. J. Fitz-Gerald, and I. Pastan, Proc. Natl. Acad. Sci. USA 86: 1008 (1989).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Per Ashorn
    • 1
  • Bernard Moss
    • 1
  • Edward A. Berger
    • 1
  1. 1.Laboratory of Viral Diseases, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations